NCT01673828View on ClinicalTrials.gov

Allopregnanolone for the Treatment of Traumatic Brain Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2016

Conditions
Traumatic Brain InjuryPosttraumatic Epilepsy
Interventions
DRUG

Allopregnanolone injection

Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium

DRUG

Placebo injection

Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium

Trial Locations (1)

95817

University of California, Davis Medical Center, Sacramento

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Michael A. Rogawski, MD, PhD

OTHER

NCT01673828 - Allopregnanolone for the Treatment of Traumatic Brain Injury | Biotech Hunter | Biotech Hunter